BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250527
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T093746
CREATED:20250307T113641Z
LAST-MODIFIED:20250307T113641Z
UID:40683-1748304000-1748563199@www.pharmajournalist.com
SUMMARY:3rd Retinal Imaging Biomarkers & Endpoints Summit
DESCRIPTION:The 3rd Retinal Imaging Biomarkers & Endpoints Summit will bring together leading experts spanning medical directors\, researchers\, clinical\, and imaging scientists from more than 30 organizations spearheading ophthalmic development with deep learning systems and sophisticated AI imaging technologies. It’s here they will explore the latest advancements in retinal imaging\, biomarkers\, and endpoints for ophthalmic drug development. \nThis highly anticipated meeting will delve into the evolving landscape of retinal diseases\, offering in-depth discussions on innovative imaging techniques\, biomarker discovery\, and the critical role of endpoints in clinical trials. Attendees will have the opportunity to engage with top-tier scientists\, researchers\, and industry leaders who will be presenting cutting-edge research\, techniques\, and case studies\, providing you with hyper-relevant insights to accelerate your ophthalmic development. \nTopics will cover a range of retinal conditions\, including dry and wet AMD\, GA\, GR\, and DME\, focusing on the identification and validation of biomarkers that are vital for diagnosis\, prognosis\, and treatment response assessment. This meeting is the perfect bridge for those developing and using novel technologies to ensure the efficacious development of endpoints for regulatory approval. \nAttendees will benefit from interactive workshops\, panel discussions\, and case studies\, providing practical insights into the real-world challenges and opportunities in retinal disease research. Plus\, with 8+ hours of dedicated networking sessions designed to ensure attendees get to meet everyone in the room\, it’s a fantastic opportunity to build valuable connections and strengthen collaboration which will aid in fostering partnerships that will drive the future of retinal imaging and treatment outcomes. \nAnd with sessions being delivered by Alexion\, Opus Genetics\, Inflammx\, Bausch + Lomb\, REGENXBIO\, and many more you won’t want to miss this! \nWhether you’re a researcher\, drug developer\, clinician or solution provider\, the 3rd Retinal Imaging Biomarkers & Endpoints Summit promises to be a pivotal point in the calendar for those involved in the development of therapies for retinal diseases. \nJoin us to be at the forefront of this rapidly advancing field and contribute to the next wave of innovations in retinal health… \nView the event guide for more information: https://ter.li/hcmzr0 \nSecure your pass: https://ter.li/tq8jmz
URL:http://www.pharmajournalist.com/event/3rd-retinal-imaging-biomarkers-endpoints-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250527
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T093746
CREATED:20250416T103747Z
LAST-MODIFIED:20250416T103747Z
UID:40951-1748304000-1748563199@www.pharmajournalist.com
SUMMARY:2nd Cell & Gene Therapy Pricing & Reimbursement Summit
DESCRIPTION:Current limitations across pricing\, coverage\, and payment frameworks are lasering out and hindering global access to many approved cell and gene therapies (CGTs). The Cell & Gene Therapy Pricing & Reimbursement Summit is here to change that. \nReturning for its 2nd edition\, this unique summit will share real-world case studies of success and setback in ensuring patients can access CGTs to spearhead reform in this thorny landscape. \nIndustry-led discussions will center on innovative payment models being developed and applied\, new stop-loss and reinsurance programs\, and how leading companies are ensuring coverage and uptake of their commercialized therapies. You’ll also leave with actionable learnings from recent CMS policy changes\, including the Access Model\, Medicaid Drug Rebate Program Final Rule\, and proposed increases to inpatient CAR-T reimbursement rates. \nJoin leading biopharma\, government agencies\, commercial payers\, academics\, and market access-specialist service providers – to align on the current market access strategy and policy challenges hindering widespread adoption of these ground-breaking therapies\, enhance your payer coverage and improve patient access. \nTo know more visit: https://ter.li/0g5eq9
URL:http://www.pharmajournalist.com/event/2nd-cell-gene-therapy-pricing-reimbursement-summit/
LOCATION:Marriott Washington Capitol Hill\, 175 L Street NE\, WA\, 20002\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250528
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T093746
CREATED:20250217T143826Z
LAST-MODIFIED:20250217T143826Z
UID:40519-1748390400-1748563199@www.pharmajournalist.com
SUMMARY:4th Circular & Self-Amplifying RNA Therapeutics Summit
DESCRIPTION:Join the 4th Circular & Self-Amplifying RNA Therapeutics Summit! \nUnleashing the Next Generation of RNAs for Widespread Therapeutic Applications \nWith CSL Seqirus and Arcturus Therapeutics successfully developing the first approved self-amplifying RNA vaccine\, the field of next generation RNAs celebrates the potential of circular and self-amplifying RNAs to provide improved stability\, durability\, longevity and efficacy for treating a wide array of diseases. \nThis May\, the 4th Circular & Self-Amplifying RNA Therapeutics Summit (previously known as ‘Next Generation RNA Therapeutics Summit) is landing back in Boston\, as the unique opportunity to unite with leading stakeholders in the next generation RNA field\, including the likes of Sail Biomedicines\, Merck\, Novo Nordisk\, Replicate Bioscience and more. This is your one-stop shop to hear the latest approaches and applications of circular and self-amplifying RNA therapeutics and vaccines and gain actionable insights for fast-tracking your RNA programs toward the clinic. \nJoin 80+ RNA experts navigating through challenges such as RNA design\, delivery\, purity\, and manufacturing to accelerate high-quality and scalable next-generation RNA therapeutics and vaccines towards approval and the patients in need. \nTo know more visit: https://ter.li/lemzh2
URL:http://www.pharmajournalist.com/event/4th-circular-self-amplifying-rna-therapeutics-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250528
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T093746
CREATED:20250219T115152Z
LAST-MODIFIED:20250219T115152Z
UID:40525-1748390400-1748563199@www.pharmajournalist.com
SUMMARY:3rd Gene Therapy Potency Assay Summit
DESCRIPTION:Accelerating the Route to Commercialization with Robust Potency Assay Development \nFollowing a challenging year in the gene therapy field\, the 3rd Gene Therapy Potency Assay Summit returns at a crucial time when drug developers increasingly recognize that a robust potency assay is fundamental to both clinical success and commercial viability. As regulatory expectations continue to evolve\, it has never been more important to develop assays that are accurate\, reproducible\, and aligned with regulatory standards. \nWhile many industry meetings touch on potency in a broad or non-technical manner\, this summit stands apart as the only event fully dedicated to the complexities of potency assay development. With an emphasis on deep technical discussions\, attendees will gain unparalleled insights into phase-appropriate assay development\, methodology advancements\, reducing lot-to-lot variability\, and meeting evolving regulatory expectations. By bringing together a specialized community of Analytical Development\, Quality Control\, and Regulatory experts\, this meeting offers a unique platform to discuss challenges\, share strategies\, and explore innovative solutions. \nOne of the key highlights of this year’s agenda is the session “Navigating Regulatory Requirements for Gene Therapy Potency Assays”\, presented by Melody Dai\, Vice President\, Head of Regulatory Affairs & CMC at Novasenta. This session\, taking place at 9:00 AM on Day 1\, will provide an in-depth exploration of regulatory strategies for potency assays\, covering both early and ongoing regulatory engagement. Attendees will learn how to build effective relationships with regulatory agencies\, navigate evolving requirements\, and prepare for critical regulatory meetings and submissions. By leveraging insights from experts with hands-on experience in clinical-stage gene therapy products\, this session will offer practical guidance that extends beyond theoretical discussions. \nWith a carefully curated agenda and contributions from industry leaders\, the 3rd Gene Therapy Potency Assay Summit provides an essential opportunity to advance potency assay strategies\, enhance regulatory preparedness\, and accelerate the path to commercialization. Whether you are refining your assay methodologies\, tackling regulatory complexities\, or preparing for the next phase of development\, this event will equip you with the expertise and connections needed to drive success in gene therapy. \nFind Out More Now!
URL:http://www.pharmajournalist.com/event/3rd-gene-therapy-potency-assay-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR